Diana Osorio
Department of Pediatrics, Division of Pediatrics
About Dr. Diana Osorio
Present Title & Affiliation
Primary Appointment
Inpatient Medical Director, Department of Pediatrics - Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
Center Medical Director, Department of Pediatrics - Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Department of Pediatrics - Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2007 | Universidad Central del Caribe, Puerto Rico, Bayamón, Puerto Rico, US, MD |
Postgraduate Training
| 2013-2014 | Postgraduate Fellow, Neuro-Oncology, New York University Langone Medical Center, New York, New York |
| 2010-2013 | Postgraduate Fellow, Hematology/Oncology, Northwell Health- Cohen Children’s Medical Center, New Hyde Park, New York |
| 2007-2010 | Resident, Pediatrics, Northwell Health- Cohen Children’s Medical Center, New Hyde Park, New York |
Licenses & Certifications
| 2025 | Florida Board of Medicine |
| 2024 | Texas License |
| 2021 | American Board of Pediatrics Hematology Oncology |
| 2017 | American Board of Pediatrics |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Pediatrics, The Ohio State University, Colombus, Ohio, 2014 - 2021
Other Professional Positions
Member, Society for Neuro-Oncology, MD Anderson Cancer Center, 2020 - Present
Member, Society for Neuro-Oncology, Nationwide Children's, 2013 - Present
Extramural Institutional Committee Activities
Member, MD Anderson IRB, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Pediatric Clinical Practice Committee, American Academy of Pediatrics, 2024 - Present
Member, Pediatric Brain Tumor Consortium (PBTC) Ependymoma and Immunotherapy Committee, Nationwide Children's Hospital, 2021 - Present
Member, Pacific Pediatric Neuro-Oncology Consortium (PNOC) CNS Germ Cell Tumor Working Group, Pediatric Neuro-Oncology Consortium, 2021 - Present
Member, AACR-PLGAF Pediatric Brain Tumor Research Grants Scientific Review Committee, Nationwide Children's Hospital, 2020 - Present
Member, Team Hope, Nationwide Children's Hospital, 2016 - 2021
Member, CSRC, Nationwide Children's Hospital, 2016 - 2021
Editorial Activities
Topic Editor, Frontiers in Oncology, 2023 - Present
Journal Reviewer, Cancer Reports, 2021 - Present
Journal Reviewer, Oncology research and treatment, 2020 - Present
Journal Reviewer, Journal Pediatric Hematology Oncology, 2020 - Present
Journal Reviewer, Child Nervous System, 2019 - Present
Journal Reviewer, Cancer, 2018 - Present
Journal Reviewer, Pediatric Blood and Cancer, 2017 - 2021
Journal Reviewer, Pediatric Neurology, 2014 - 2018
Honors & Awards
| 2023 - Present | Think Tank: Genetic Predisposition to Primary CNS Cancers |
Selected Presentations & Talks
Local Presentations
- 2024. “Brain Tumors in Neurofibromatosis”. Invited. Texas Neurofibromatosis Foundation Symposium. Houston, Texas, US.
- 2024. Peds NeurOonc future clinical trials at MDA. Invited. Energy Transfer’s Fundraising Campaign Event. Houston, Texas, US.
Regional Presentations
- 2025. PNOC033 Study Updates. Pediatric Brain Tumor Consortium, US.
International Presentations
- 2025. Choroid Plexus Carcinoma Molecularly-Risk Stratified Treatment Strategy. Invited. VIVA-Asia Rare Tumor Board #17: Infant Brain Tumors – Choroid Plexus, SG.
- 2025. Central Nervous System Tumors Session. Invited. 36th SLAOP Annual Meeting and 23rd ACHOP Annual Meeting, US.
- 2024. News in the Management of Germ Cell Tumors in Pediatric Patients. Invited. 42nd National and 11th International Congress of Oncology of the Mexican Society of Oncology, US.
- 2023. Pediatric Neuro-oncology in the New Molecular Era. Invited. Mexican Association of Pediatric OncoHematology (AMOHP), US.
- 2021. Medulloblastoma Treatment Guidelines in Central America. Invited. 23rd annual Association of Pediatric Hematology Oncology in Central America, US.
- 2020. Addressing Global and Loco-Regional Disparities in the Management of Childhood Brain Cancer. Invited. Pediatric Grand Rounds Nationwide Children’s Hospital.
- 2020. Directed Medulloblastoma Treatment Guidelines in Central America. Invited. 22nd annual Association of Pediatric Hematology Oncology in Central America, US.
- 2019. Management of Infant and Childhood Medulloblastoma and the Management of Ependymoma. Invited. 8th Annual Latin American Pediatric Neurosurgery Conference, US.
- 2018. Pediatric Neuro-Oncology Pertinent to Low-to-Middle Income Countries (LMIC). Invited. Co-organizing committee member and 3rd PLANO educational conference at INEN, US.
- 2018. Association of Pediatric Hematology/Oncology of Colombia (ACHOP), Regional conference. Ependymoma and Medulloblastoma. Invited, US.
- 2018. Management of Medulloblastoma, Craniopharyngioma and Central Nervous System Germ Cell Tumors. Leo Messi Foundation Neuro-oncology Course. Invited, US.
- 2017. Experiencia de un grupo de discusión interactivo Latino Americano en tumores del SNC. Latin American Society of Pediatric Oncology (SLAOP). Invited, US.
- 2016. Pediatric Brain Tumors Session, Session Organizer and Moderator: Pediatric Brain Tumor Patient Cases and Discussion of their Management, Association of Pediatric Hematology/Oncology Central America. Invited, US.
- 2015. First International Pediatric Latin American Neurooncology (PLANO) at GRACC Institute; Management of Low Grade Gliomas and Management of ATRT/PNET. Invited, US.
- 2013. Prevalence of elevated erythrocyte adenosine deaminase activity, a marker for Diamond Blackfan Anemia in patients with congenital heart disease. Poster. American Society of Peditaric Hematology Oncology, US.
- 2013. Dasatinib in children and adolescents with central nervous system germ cell tumors. Poster. Third International CNS Germ Cell Tumor Symposium, US.
- 2009. Irradiation-avoiding strategies in the management of young children with newly diagnosed central nervous system embryonal tumors: 18 years of three serial chemotherapy regimens – the “Head Start” Protocols. Invited. Thirty-fifth Annual Meeting of the Korean Cancer Society, US.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy |
| Funding Source: | Eli Lilly |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | DIPG/DMG Psychosocial Support: Grief-informed interventions to bolster meaning and reduce emotional distress |
| Funding Source: | Children's Brain Tumor Foundation |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | Phase II Trial Evaluating Chemotherapy Followed by Response- Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas |
| Funding Source: | COG |
| Role: | Co-PI |
| ID: | ACNS2321 |
| Date: | 2025 - Present |
| Title: | Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
| Funding Source: | NCI |
| Role: | Co-PI |
| ID: | ACNS1931 |
| Date: | 2025 - Present |
| Title: | DIPG/DMG Psychosocial Support: Grief-informed interventions to bolster meaning and reduce emotional distress |
| Funding Source: | Children's Brain Tumor Foundation |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations |
| Funding Source: | ACNS |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas |
| Funding Source: | ACNS |
| Role: | Co-PI |
Selected Publications
Peer-Reviewed Articles
- Oigman G, Gonzaga Y, Christiani M, Magalhaes D, Moreira V, Osorio DS, Ferman S. Survival of pediatric patients with ependymoma in a tertiary cancer center in Rio de Janeiro, Brazil. Front. Oncol, 2024. e-Pub 2024.
- Rajagopal R, Coronado RD, Hamid SA, del Campo RNM, Boop F, Bag A, Benito Reséndiz AE, Vasudeva Bhat K, Campos D, Chang K, Cirt R, Rahmartani LD, Foo JC, Hoveyan J, Lucas Jr JT, Ngcana T, Ain RU, Omran N, Osorio DS, Qureshi BM, Sabin ND, Schandorf E, Bankah P, Dadzie M, Gbadamos H, Sharafeldin H, Somathilaka M, Yang P, Jean-Jacques YA, Zhang A, Salman Z, Gonzalez M, Friedrich P, Rodriguez-Galindo C, Qaddoumi I, Moreira DC. Development of the pediatric neuro-oncology services assessment aid: An assessment tool for pediatric neuro-oncology service delivery capacity. NOA 6(1), 2024.
- Giro´ n AV, Blanco-Lopez J, Calderon P, Jiron R, Pineda E, Montero M, Lizardo Y, Bartels U, Osorio DS. Primary central nervous system germ cell tumors in Central America and the Caribbean Region: an AHOPCA 20-year experience. Front. Oncol, 2024. e-Pub 2024.
- Osorio DS, Yankelevich M, Zaky WT, Lafay-Cousin L, Margol AS, Toll S, Quiroz L, Fox JE, Hanson D, Gardner SL, Prados M, Mueller S, L Finlay AJ. Marrow-ablative consolidation chemotherapy (HDCT) to decrease the development of choroid plexus carcinoma (CPC) specific relapse in high-risk TP53-mutated (germline or somatic) young children with newly diagnosed CPC. JCO 42(16), 2024. e-Pub 2024.
- Salceda-Rivera V, Tejocote-Romero I, Osorio DS, Bellido-Magaña R, Lo´ pez-Facundo A, Anaya-Aguirre SE, Ortiz-Morales D, Rivera-Luna R, Reyes-Gutie´ rrez E, Rivera-Go´ mez R, Velasco-Hidalgo L, Corte´ s-Alva D, Lagarda-Arrechea S, Arregu´ın-Gonza´lez FE, Benito-Rese´ ndiz AE, Cha´ vez-Gallegos S, Pe´rez-Rivera E, Gayta´ n-Ferna´ ndez GJ, Leo´ n-Espitia JA, Dom´ınguez-Sa´ nchez J, Leal-Cavazos C, Simo´ n-Gonza´lez C, Larios-Farak TC, Mac´ıas-Garc´ıa NA, Garc´ıa-Espinosa AC, Guerrero-Maymes F, Casillas-Toral P, Gonza´lez-Ramella O. Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico. Front. Oncol 14, 2024. e-Pub 2024.
Editorials
- Osorio, DS, Qaddoumi, I, Moreira, DC. Editorial. Frontiers in Oncology 15, 2025. PMID: 39931086.
Patient Reviews
CV information above last modified September 11, 2025